QuellTX
Jodie Albutt has a diverse work experience in intellectual property (IP) spanning several notable companies. Jodie began their career as a Patent Attorney at Dehns in September 2001 and worked there until July 2015. Jodie then joined Cell and Gene Therapy Catapult in August 2015 as an In-house Patent Attorney and later became the Head of IP from February 2018 to September 2019. In 2019, Jodie joined Quell Therapeutics as the Head of IP and later transitioned to the role of VP, IP in July 2021.
Jodie Albutt has a strong education background in the field of biology. Jodie completed their Bachelor's Degree in Biology, General at Imperial College London from 1995 to 1998. Following this, they pursued a Doctor of Philosophy (Ph.D.) in Molecular Biology at King's College London from 1998 to 2001.
In addition to their academic achievements, Jodie has obtained several certifications. Jodie received an Intellectual Property Litigation Certificate in December 2012 from THE INTELLECTUAL PROPERTY REGULATION BOARD LIMITED. Jodie also holds a BSc Biology from Imperial College and a Certificate in Intellectual Property Law from Queen Mary University of London. Jodie is recognized as a Chartered patent attorney by The Chartered Institute of Patent Attorneys and also holds the title of European patent attorney from the European Patent Office. Although the specific months and years of obtaining these certifications are not provided, it is evident that Jodie has pursued and been awarded multiple qualifications in the field of intellectual property law and biology.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.